MiNK Therapeutics (INKT) Return on Capital Employed (2021 - 2026)
MiNK Therapeutics (INKT) posted Return on Capital Employed of 255.42% for Q1 2026, up 68.28% sequentially from 805.32% in Q4 2025, and down 39797.0% YoY from N/an in Q1 2025.
MiNK Therapeutics (INKT) Return on Capital Employed (2021 - 2026) Analysis & Trends
MiNK Therapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 255.42% in Q1 2026.
- Quarterly Return on Capital Employed fell 39797.0% year-over-year to 255.42% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 255.42% (down 39797.0% YoY) and the FY2025 annual result came in at 414.27%, down 20488.0% from the prior year.
- Return on Capital Employed improved to 255.42% in Q1 2026 per INKT's latest filing, from 805.32% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 4167.75% in Q3 2023 and troughed at 985.13% in Q3 2024.
- A 5-year average of 294.97% and a median of 169.05% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed surged 446976 bps in 2023, then slumped 515287 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 289.69% in 2022, then jumped by 247 bps to 424.81% in 2023, then surged by 545 bps to 2740.5% in 2024, then sank by 129 bps to 805.32% in 2025, then jumped by 68 bps to 255.42% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 255.42%, 805.32%, and 264.12% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 7.88% |
| 10 | MiNK Therapeutics | 61.20 Mn | 61.20 Mn | - | -493.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -493.87% |
| Mar 31, 2026 | -255.42% |
| Dec 31, 2025 | -805.32% |
| Sep 30, 2025 | 264.12% |
| Jun 30, 2025 | 113.82% |
| Mar 31, 2025 | 142.56% |
| Dec 31, 2024 | 2,740.50% |
| Sep 30, 2024 | -985.13% |
| Jun 30, 2024 | 1,145.51% |
| Mar 31, 2024 | 388.05% |
| Dec 31, 2023 | 424.81% |
| Sep 30, 2023 | 4,167.75% |
| Jun 30, 2023 | -972.92% |
| Mar 31, 2023 | -378.26% |
| Dec 31, 2022 | -289.69% |
| Sep 30, 2022 | -302.01% |
| Jun 30, 2022 | -214.85% |
| Mar 31, 2022 | -169.05% |
| Dec 31, 2021 | -498.01% |